3D Systems
DDD
3.41
-0.18
-5.01%
3D Systems
US · DDD
#3666 by market cap
Listed 2011
3.41
-0.18
-5.01%
Live - 5344 symbols - heartbeat 230s ago
· 2026-10-08 07:56
Pre-market
3.37
-1.28%
After-hours
3.41
0.00%
Overnight
3.41
0.00%
- Market cap
- 566.56M
- P/E (TTM)i
- -8.53
- P/Bi
- 2.07
- EPSi
- 0.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on DDD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 76.29% +0.02pp
- Institutions
- 242 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund43.62%
Hedge Fund22.39%
Public Company5.52%
Individual/Insider3.43%
Private Company1.85%
Insurance Company1.67%
Family Office/Trust1.16%
Other20.29%
Top holders as of 2026-06-30
BlackRock
8.18% · 13.59M sh
State Street Global Advisors
7.99% · 13.27M sh
Vanguard Capital Management, LLC
4.70% · 7.81M sh
Aigh Capital Management, LLC
4.38% · 7.27M sh
Two Sigma Investments, LP
3.95% · 6.56M sh
The Bank of Nova Scotia
3.16% · 5.25M sh
D. E. Shaw & Co., L.P.
2.56% · 4.26M sh
Marshall Wace LLP
2.37% · 3.93M sh
Geode Capital Management, LLC
2.26% · 3.76M sh
Needham Investment Management, LLC
2.12% · 3.53M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Jeffrey Graves | Chief Executive Officer | 0.74% |
| Phyllis Nordstrom | Executive VP, Chief People Officer & Chief Administrative Officer | 0.43% |
| Jim Kever | Independent Director | 0.34% |
| Charles Hull | Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus | 0.31% |
| Reji Puthenveetil | Executive Vice President of Industrial Solutions | 0.29% |
| Thomas Erickson | Independent Director | 0.24% |
| Kevin Moore | Independent Director | 0.19% |
| Joseph Zuiker | Executive Vice President of Engineering & Operations | 0.16% |
| Charles McClure | Independent Chairperson | 0.14% |
| John Tracy | Independent Director | 0.14% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Jeffrey Graves | Chief Executive Officer | Open Market Disposition | -42,686 | $3.55 |
| 2026-09-16 | Phyllis Nordstrom | Executive VP, Chief People Officer & Chief Administrative Officer | Open Market Disposition | -30,000 | $3.58 |
| 2026-09-07 | Charles Hull | Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus | Sale to Issuer | -4,943 | $3.38 |
| 2026-09-07 | Jeffrey Graves | Chief Executive Officer | Sale to Issuer | -39,959 | $3.38 |
| 2026-09-07 | Phyllis Nordstrom | Executive VP, Chief People Officer & Chief Administrative Officer | Sale to Issuer | -47,396 | $3.38 |
| 2026-09-07 | Andrew Wright | Senior VP of General Counsel & Corporate Secretary | Sale to Issuer | -5,818 | $3.38 |
| 2026-09-07 | Reji Puthenveetil | Executive Vice President of Industrial Solutions | Sale to Issuer | -15,984 | $3.38 |
| 2026-09-07 | Joseph Zuiker | Executive Vice President of Engineering & Operations | Sale to Issuer | -6,689 | $3.38 |
| 2026-08-19 | Jeffrey Graves | Chief Executive Officer | Open Market Disposition | -115,500 | $3.26 |
| 2026-05-13 | Jim Kever | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Thomas Erickson | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Kevin Moore | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Charles McClure | Independent Chairperson | Other Acquisition | +45,731 | -- |
| 2026-05-13 | John Tracy | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Malissia Clinton | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Vasant Padmanabhan | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-05-13 | Claudia Drayton | Independent Director | Other Acquisition | +45,731 | -- |
| 2026-04-13 | Charles Hull | Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus | Sale to Issuer | -4,102 | $1.98 |
| 2026-04-13 | Jeffrey Graves | Chief Executive Officer | Sale to Issuer | -30,500 | $1.98 |
| 2026-04-13 | Phyllis Nordstrom | Executive VP, Chief People Officer & Chief Administrative Officer | Sale to Issuer | -1,626 | $1.98 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:56:58 · For reference only, not investment advice and not tailored to your situation.